BC Extra | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

Emgality meets in Phase III in pretreated migraine patients  Eli Lilly and Co. (NYSE:LLY) reported that anti-CGRP mAb Emgality galcanezumab-gnlm met the primary endpoint in the Phase III CONQUER trial, reducing migraine headache days by...
BC Week In Review | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said both doses of ensifentrine (RPL554) given on top of dual bronchodilator therapy missed the primary endpoint in a Phase II trial as maintenance treatment of chronic obstructive pulmonary disease...
BC Week In Review | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIb trial in 403 patients with moderate to severe chronic obstructive pulmonary disease (COPD) showing that all four doses of RPL554 (VMX554, VRP554) as...
BC Week In Review | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in 10 cystic fibrosis patients showing that single doses of 1.5 and 6 mg RPL554 (VMX554, VRP554) both significantly increased mean forced...
BC Week In Review | Oct 13, 2017
Clinical News

Verona reports Phase IIa data for RPL554 in COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in patients with chronic obstructive pulmonary disease (COPD) showing that twice-daily 1.5 and 6 mg doses of RPL554 (VMX554, VRP554) plus Spiriva...
BC Week In Review | Jun 9, 2017
Clinical News

Verona begins PK trial for RPL554 in healthy volunteers

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) began a 2-way crossover, U.S. trial to evaluate the bioavailability, pharmacokinetics and safety of nebulized RPL554 in 12 healthy volunteers. Data from the trial are expected in 4Q17. The nebulized...
BC Extra | Apr 27, 2017
Financial News

Verona raises $80M, lists on NASDAQ

Respiratory disease company Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) traded flat on NASDAQ Thursday, ending the day at $13.50, after it raised $80 million in a NASDAQ listing and concurrent private placement, both underwritten by Jefferies,...
BC Week In Review | Apr 7, 2017
Clinical News

RPL554: Ph IIa started

Verona began a double-blind, placebo-controlled, 3-way crossover, U.K. Phase IIa trial to evaluate single doses of 1.5 and 6 mg inhaled RPL554 in about 10 patients. In 2005, Verona licensed the product from Vernalis, which...
BC Extra | Apr 4, 2017
Financial News

Verona seeking NASDAQ listing

Pulmonary and inflammatory diseases company Verona Pharma plc (LSE:VRP) filed to raise up to $86.3 million in a listing of ADSs on NASDAQ underwritten by Jefferies, Stifel, Wedbush PacGrow and Suntrust. Verona expects data in...
BC Week In Review | Feb 24, 2017
Clinical News

RPL554: Ph IIa started

Verona began a double-blind, placebo-controlled, 3-way crossover, U.K. Phase IIa trial to evaluate 1.5 and 6 mg inhaled RPL554 once daily plus 10 µg Spiriva tiotropium once daily in about 30 patients. In 2005, Verona...
Items per page:
1 - 10 of 34